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Asymmetric parental genome
engineering by Cas9 during mouse
meiotic exit
Toru Suzuki*, Maki Asami* & Anthony C. F. Perry
Laboratory of Mammalian Molecular Embryology, Department of Biology and Biochemistry, University of Bath, BA2 7AY, England.
Mammalian genomes can be edited by injecting pronuclear embryos with Cas9 cRNA and guide RNA
(gRNA) but it is unknownwhether editing can also occur during the onset of embryonic development, prior
to pronuclear embryogenesis. We here report Cas9-mediated editing during sperm-induced meiotic exit
and the initiation of development. Injection of unfertilized, mouse metaphase II (mII) oocytes with Cas9
cRNA, gRNA and sperm enabled efficient editing of transgenic and native alleles. Pre-loading oocytes with
Cas9 increased sensitivity to gRNA ,100-fold. Paternal allelic editing occurred as an early event: single
embryo genome analysis revealed editing within 3 h of sperm injection, coinciding with sperm chromatin
decondensation during the gamete-to-embryo transition but prior to pronucleus formation. Maternal
alleles underwent editing after the first round of DNA replication, resulting in mosaicism. Asymmetric
editing of maternal and paternal alleles suggests a novel strategy for discriminatory targeting of parental
genomes.
G
ene-targeted mice facilitate functional genetic analysis in vivo but the manner in which they are typically
produced via embryonic stem (ES) cells is laborious, time-consuming and expensive. Gene targeting in
larger species, although increasingly relevant in biomedicine, is even more difficult.
Recently, two structurally-discrete classes of DNA binding domain, zinc finger nucleases (ZFNs) and tran-
scription activator-like effector nucleases (TALENs), have been used to generate sequence-specific intracellular
double-strand DNA breaks in metazoan genomes. ZFN- or TALEN-generated breaks may be repaired by error-
prone nonhomologous end joining (NHEJ) to generate insertions or deletions (indels) that produce non-func-
tional (null) alleles in culturedmammalian cells or single-cell embryos1,2. ZFN-generated double-strand breaks in
cultured cells stimulate high-fidelity homology-dependent repair (HDR) by several orders of magnitude3–5 and
enable HDR-mediated gene targeting in mouse and rat single-cell embryos (known as zygotes) at efficiencies of
2.4–25% (Ref. 1). However, the production of ZFNs and TALENs is complex, and pairs of each must be tailor-
made for each targeted region. The efficiency of targeting is also variable and animals have not been produced by
simultaneous ZFN- or TALEN-mediated targeting of multiple alleles.
These barriers have recently been negotiated by a powerful newcomer to mammalian genome engineering
technology: the clustered, regularly interspaced, short palindromic repeat (CRISPR)/Cas9 system of adaptable
bacterial immunity6,7. Cas9 is a DNA endonuclease whose site-specificity is determined by a single-stranded
CRISPR RNA. CRISPR RNAs have beenmodified from their original bacterial source (eg Streptococcus pyogenes)
and Cas9 codon-optimized to function effectively in mammalian cells6,8. The Cas9 system differs from ZFN and
TALEN technologies because it utilizes a single protein - Cas9 - for all modifications, with target specificity
provided bymodified CRISPR guide RNA (gRNA). The gRNA contains a 20 nucleotide (nt) sequence that forms
a heteroduplex with its complementary DNA target (frequently on the genome), which can be any sequence
upstream of the proto-spacer adjacent motif (PAM), NGG6. Typical gRNAs are relatively short (,110 nt)6 and
thus easy to synthesize. With these advantages, the Cas9 system has rapidly been adopted to introduce targeted
mutations in yeast, plants, Drosophila, C. elegans, zebrafish, mice, rats, pigs and macaques (reviewed in Ref. 9).
Cas9 has been used for multiplex targeting, with one-step NHEJ-mediated editing of 8 alleles at an efficiency of
10% in human cultured cells and biallelic editing with an 80% hit-rate in single-cell mouse embryos (pronuclear
zygotes)10. Efficient early embryonic genome targeting is especially promising because it leads directly to mutant
offspring11–14.
In fertilization, sperm combine with metaphase II (mII) oocytes and become denuded of nucleoprotein
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and form a nuclear structure, the pronucleus15–17. (The maternal
genome simultaneously forms a separate pronucleus.) The early
phase in which sperm decondensation occurs coincides with the
gamete-to-embryo transition and supports efficient transgene integ-
ration at quasi-random sites18,19; transgenes preferentially integrate
into the sperm-derived genome (rather than the oocyte-derived gen-
ome), possibly because protein depletion during sperm decondensa-
tion makes it a better substrate for recombination17. This suggests
that the paternal genomemight also be a relatively good substrate for
Cas9-mediated genome engineering20. We sought to test this pos-
sibility and report that Cas9 promotes high-efficiency genome
editing in the decondensation phase that immediately follows intra-
cytoplasmic sperm injection (ICSI) of unfertilized mII oocytes (Fig. 1A).
Results and discussion
To evaluate genome editing during meiotic exit, we first generated a
test-bed transgenic line (129-eGFP) by introducing a single-copy
ubiquitously-expressed pCAG-eGFP transgene (eGFP) onto the
129/Sv background. When sperm heads from 129-eGFP hemizy-
gotes (ie eGFP1/2 males) were injected into wild-type (wt) B6D2F1
mII oocytes and the resulting embryos cultured, over-all, 90.5%
(n5116) developed to the blastocyst stage by embryonic day 4
(E4.0), of which 46.6% fluoresced green, indicating that they
expressed a functional eGFP gene (Fig. 1B,C). When sperm from
129-eGFP hemizygous males were coinjected with 100 ng/ml
cRNA encoding Cas9 and 200 ng/ml eGFP gRNA (the 1-step method
of Fig. 1A), 93.3% developed to the blastocyst stage (n557) but none
(0%) fluoresced green (Fig. 1B,C). This is the expected result if the
eGFP alleles had been efficiently edited to become non-functional.
When we titrated Cas9 cRNA and eGFP gRNA under these condi-
tions, we found that they were effective at concentrations at or above
1–10 ng/ml (Fig. 1C). Paternal mosaicism was occasionally observed
at near-threshold concentrations of active gRNA (,1 ng/ml; asterisk
in Fig. 1B).
Our previous work has shown that cRNA injected intomII oocytes
takes 3,4 h before it is discernibly expressed21,22. We therefore rea-
soned that loading mII oocytes with Cas9 cRNA prior to sperm/
gRNA injection might enhance editing by lengthening the time for
Cas9 expression. To investigate this, we sequentially injected oocytes
first with Cas9 cRNA and after 3,4 h, eGFP gRNA plus sperm from
a 129-eGFP hemizygote (Fig. 1A). As in the 1-step method, the Cas9
system efficiently eliminated green fluorescence compared to con-
trols (Fig. 1B–D). These results were confirmed by analogous experi-
ments with aNanog-eGFP knock-in line (Fig. 1E and Supplementary
Fig. S1A). This shows that genome targeting by injecting mII oocytes
with sperm, Cas9 cRNA and gRNA can be achieved high efficiencies
and is not locus-specific.
To evaluate whether the sequential injection enhanced editing, we
performed a comparative titration of gRNA (1-step vs sequential
methods), holding the concentration of injectedCas9 cRNA constant
and non-limiting at 100 ng/ml (Fig. 1B–D). Editing in the 1-step
method became inefficient when,1 ng/ml eGFP gRNA was injected
(Fig. 1C). However, a similar editing efficiency in the sequential
method was obtained with 0.01 ng/ml eGFP gRNA, corresponding
to ,7 3 108 gRNA molecules per injection (Fig. 1C). Therefore, in
these experiments, the sequential method of Cas9-mediated paternal
genomic editing was ,100-fold more sensitive than the 1-step
method. One interpretation of this finding is that the potential for
Figure 1 | Cas9-mediated editing inmII exit following ICSI. (A) Schematic of 1-step (upper) and sequentialmethods of Cas9-mediatedmII editing. mII,
metaphase II. (B) Paired Hoffman modulation (upper) and eGFP expression (eGFP) images of E4.0 blastocysts produced by 1-step injection of wt mII
oocytes with 129-eGFP sperm from hemizygotes, with concentrations of injected Cas9 cRNA and eGFP gRNA indicated below. An asterisk indicates a
presumptively phenotypic mosaic. Bar, 100 mm. (C) Numerical representation of embryo development and green fluorescence following injection of
sperm from 129-eGFP hemizygous males. Percentages are of blastocyst development on embryonic day 4 (E4.0) (open) and of blastocysts that fluoresced
green (filled) indicating 129-eGFP transgene expression in 1-step (green) or sequential (red) methods. Starting embryo numbers and injected
concentrations ofCas9 cRNA and eGFP gRNA (gRNA) are shown beneath. (D) PairedHoffmanmodulation (upper) and eGFP expression (eGFP) images
as for (B) except that the sequential method of injection (Fig. 1A) was used. (E) Histograms as for (C) except that one of either the injected sperm (left) or
oocyte carried a Nanog-eGFP knock-in allele. Red highlights provide at-a-glance indication of RNA concentrations in (B) to (E).
www.nature.com/scientificreports
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editing in the 1-step method declines before sufficient Cas9 has been
synthesized, implying that paternal genome editing is generally an
early event.
To assess Cas9 activity towards the maternal genome, wt B6D2F1
sperm were injected into oocytes from females carrying an eGFP
transgene. Interpretation of these experiments in the 129-eGFP line
was confounded by carry-over of eGFP protein expressed during
oocyte maturation, but the problemwas mitigated with oocytes from
Nanog-eGFP hemizygotes, in which there is little or no carry-over
(Fig. 1E and Supplementary Fig. S1B). Following injection with
200 ng/ml gRNA and 100 ng/ml Cas9 cRNA, which targeted the
paternal genome with ,100% efficiency, 4.0% of E4.0 blastocysts
were GFP-positive (49,n,58, p,0.0005) (Fig. 1E and Supple-
mentary Fig. S1B).
Direct sequencing of reverse-transcriptase PCR amplimers corres-
ponding to paternal eGFP transcripts (ie derived from a sperm-borne
eGFP transgene) in completely non-green-fluorescent E4.0 blasto-
cysts produced unambiguous reads (Fig. 2A,B). The unmixed
sequences revealed that single targeting events had occurred to pro-
duce indels within or immediately 5’ of the gRNA-matching eGFP
genomic segment (n526) for both sequential and 1-step editing,
whether pCAG-eGFP or Nanog-eGFP transgenes were targeted
(Fig. 2A,B). However, targeting of maternal pCAG-eGFP or Nanog-
eGFP transgenes derived from oocytes typically (in 14/15 cases) pro-
duced sequence mosaicism (Fig. 2C). In some cases, the sequence
ambiguity suggested that cells contained a non-mutated allele as well
as amutated one (Fig. 2C) andNanog-eGFPmutations were detected
in two green fluorescent embryos, presumably either reflecting
mosaicism or functionality retained by mutated eGFP alleles.
These findings suggest that parent-of-origin-specific chromatin
behaviour during the gamete-to-embryo transition leads to parental
asymmetries in Cas9-mediated genome editing. The generation in
most cases of mixed maternal alleles (mosaicism) where only one
allele was available for editing indicates thatmaternal genome editing
usually occurred after DNA replication (S-phase). Although mater-
nal editing typically occurred after S-phase, paternal genome editing
at non-limiting Cas9 and gRNA concentrations was usually complete
pre-S-phase, giving rise to a single event that removed the gRNA
target and prevented subsequent editing. Since pCAG-eGFP or
Nanog-eGFP transgenic lines are present in different backgrounds,
this phenomenon is allele- and strain-independent.
We next sought to delineate the time-frame for paternal genome
editing. To do this, we performed single-cell whole genome amp-
lification and target locus genomic PCR after wt oocytes had been
coinjected with eGFP transgene-carrying sperm plus Cas9 and gRNA
(Fig. 2D). To increase the likelihood of detecting editing in single
cells, we used males from a different line carrying 2 eGFP transgene
copies. Sampling was 3 h after injection. All five (100%) of the trans-
genic 1-cell embryos analyzed had undergone editing of at least one
genomic copy of eGFP (Fig. 2D). The 3 h editing time-frame corre-
sponds to the period in which sperm decondensation occurs
(Fig. 2E,F), well before pronuclear formation or the onset of mitotic
S-phase after ,7 h23. This distinguishes Cas9-mediated editing fol-
lowing mII oocyte injection from that following injection of pro-
nuclear zygotes which have entered the mitotic cell cycle and
accordingly contain mitotic chromatin17.
We next evaluated editing of native alleles in the gamete-to-
embryo transition and monitored transmission of mutations to off-
spring. Tyr was chosen because its null phenotypes are readily
detectable: Tyr mutations in C57BL/6 (black) mice result in a white
coat colour and/or changes in eyemorphology and pigmentation24,25.
Cas9 cRNA and Tyr gRNA were coinjected with wt C57BL/6 sperm
into wt C57BL/6 oocytes and resultant 2-cell embryos transferred to
pseudo-pregnant recipient surrogate mothers. Some experiments
included an inert gRNA directed against Foxn1. Between 14.8 and
24.0% of founders exhibited complete or mosaic phenotypes
expected for loss of Tyr function for 1-step and sequential methods
(Table 1; Supplementary Fig. S2). These comprised loss of pigmenta-
tion in fur and both eyes, sometimes predisposing to ophthalmic
irregularities or anophthalmia26.
Most (23/27, 85.2%) founder phenotype changes only affected
part of the mouse (Supplementary Fig. S2A), reflecting somatic
mosaicism and showing that editing had occurred after the first S-
phase. We investigated this by sequencing DNA from offspring with
and without white coat or eye phenotypes (Supplementary Fig. S3A,
B). Most of the founders with evident phenotypic alterations con-
tained one or more Tyr mutations (Supplementary Fig. S3A). In
addition, many (4/6) randomly-selected founders with no discern-
able phenotypic changes also possessed Tyr mutations. Mutations
were typically (10/12) of the mixed type (Supplementary Fig. S3A).
Since a similarmixed pattern ofmutations was observed formaternal
alleles of eGFP (Fig. 2C) the phenomenon is not locus- or sequence-
specific. Consistent with our findings, multiple edited alleles have
also been observed following injection of Cas9/gRNA components
into pronuclear zygotes25.
Mutations were transmitted to offspring, including inheritance of
the non-pigmented eye phenotype in F1 progeny of coat colour
founders (with overtly normal eyes), indicating that coat colour
and eye phenotypes have a shared aetiology and further revealing
founder mosaicism (Supplementary Fig. S2 and Supplementary Fig.
S3B).
These experiments demonstrate that injecting mII oocytes with
Cas9 cRNA, gRNA and sperm efficiently produces embryos and
offspring with edited genomes. Single cell analysis revealed that
editing was detectable by 3 h. This period (the first 3 h) overlaps
with the gamete-to-embryo transition involving meiotic exit, sperm
decondensation (Fig. 2E,F) and polar body cytokinesis27,28 and pre-
cedes by several hours the appearance of pronuclear structures that
define the zygote. Recombination within 3 h of sperm delivery
would account for the distinctive patterns of paternal and maternal
editing we observed (Fig. 2A–C) if sperm decondensation provided
a unique genomic opportunity for recombination. Editing of the
paternal allele removes the gRNA target, precluding subsequent
editing. We did not detect mixed-type paternal allelic editing under
optimal, non-limiting conditions (Fig. 1B,C), suggesting that editing
occurred during developmental onset, prior to S-phase. By contrast,
edited maternal alleles were typically mixed (Fig. 2C). Editing when
the Cas9 system is injected into pronuclear zygotes also causes
mosaicism25, indicating that the same mechanism operated. This
implies that, consistent with observations in transgenesis18, meiotic
exit and the gamete-to-embryo transition do not efficiently support
maternal genome editing, plausibly because the structure of mater-
nal chromatin during this phase is refractory to the editing
machinery. Although the maternal genome is inherently refractory
to editing in the gamete-to-embryo transition, the limitted evidence
here for paternal genome editing in zygotes presumably reflects the
removal of available targets by efficient editing at the earlier stage
(Fig. 2F).
Genome editing during meiotic progression has several practical
implications. The possibility that the paternal genome is preferen-
tially targeted during decondensation implies that it might be pos-
sible to devise strategies to alter only one parental allele
prescriptively, even where both have identical DNA sequences.
Selective editing of the paternal allele, for example, may have utility
in the study of imprinting or to alter subtle deleterious (epi)muta-
tions. The relative recombinogenicity of decondensing paternal
chromatin also opens the possibility that it might support a broader
repertoire of targeting strategies, including the use of ‘nickases’ (Ref.
28), nuclear transfer, different delivery platforms29, and the efficient
deletion12 or integration30 of large DNA fragments; a comprehensive
evaluation of large fragment targeting would benefit from a more
complete description of HDR in mammalian mII oocytes20.
www.nature.com/scientificreports
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In addition, editing during the gamete-to-embryo transition may
have utility in larger species. Although obtaining pronuclear zygotes
is relatively straightforward in the mouse, this is not always the case
for large commercial breeds and the efficiency of integration and
transmission of exogenous DNA remains low31. The use of mII
oocytes, which in some species (eg pigs) can be derived by in vitro
Figure 2 | Sequence analysis reveals allelic asymmetry in parental genome mII editing. (A) Sequences of reverse-transcriptase PCR products from
embryonic day 4 (E4.0) blastocysts developing after the 1-stepmethod of editing (Fig. 1A) inwhichCas9 cRNA and eGFP gRNAwere co-injected intomII
oocytes with sperm from 129-eGFP single-copy hemizygotes (eGFP single). The gRNA-target sequence (green typeface) plus adjacent 59 sequence is
displayed on the top row and mutants beneath (grey typeface), with the corresponding Cas9 cRNA (c) and eGFP gRNA (g) concentrations (ng/ml) that
were injected to produced them. The proto-spacer adjacentmotif (PAM) is highlighted in green.Mutations are indicated in red typeface. 591, mutations
detected 59 (but not 39) of the displayed sequence. (B) Sequences of editing mutants produced as per (A), by injecting sperm from 129-eGFP (upper) or
Nanog-eGFP knock-in hemizygotes with wt oocytes, except by the sequential method (Fig. 1A). (C) Sequences of editing mutants as for (A), except that
the transgenic alleles were maternal; wt 129 sperm were injected into mII oocytes obtained from 129-eGFP single copy (upper) orNanog-eGFP knock-in
hemizygotes. 39 1, mutations were detected 39 of the displayed sequence. Yellow highlighting indicates ambiguous calls presumptively produced by
multiple targeting events. (D)Whole genome amplification of individual embryos collected 3 h after injection with sperm from a hemizygous transgenic
line (eGFP multi) carrying two copies of the eGFP transgene. The annotation used is as for (C). Red highlights provide at-a-glance indication of RNA
concentrations in (A) to (D). (E) Merged confocal immunofluorescence images of single embryos at the times indicated (h) after ICSI, showing DNA
labelled with propidium iodide (red) and antibody labeling (green) of tubulin-a (Tuba, upper panels) or histone H1 (H1). Both sperm and oocytes were
wt. White arrowheads indicate paternal chromatin. Bar, 100 mm. (F) Schematic depicting a model for Cas9-mediated editing following injection of mII
oocytes (mII). Limitted editing of maternal alleles during the gamete-to-embryo transition is inherent to the system, whereas limitted editing of paternal
alleles in zygotes is because available targets have already been removed. Pb2, second polar body; pn, pronucleus.
www.nature.com/scientificreports
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maturation, may address this limitation, with delivery of the editing
system by ICSI32 or other methods29. Finally, ICSI in human assisted
reproduction is widely used33 and this or analogous approaches may
one day enable human genome targeting or editing during very early
development. This formal possibility will require exhaustive evalu-
ation, but if successful, could enable genomic surgery for gene repair
during the initiation of embryogenesis.
Methods
Animals. Animal procedures complied with the statutes of the Animals (Scientific
Procedures) Act, 1986, approved by the University of Bath Animal Welfare and
Ethical Review Body and the Biosciences Services Unit.Wild-typemouse strains were
bred from stocks in-house or otherwise supplied by Charles River (L’Arbresle,
France). A pCAG-eGFP transgene was introduced into the 129Sv background to
produce multi- and single-copy, high-expressing lines18, and additional transgenic
lines were generated in-house or were kind gifts and contained pCAG-eGFP or
pNanog-eGFP transgenes on mixed background hybrid lines containing a
contribution from C57BL/6.
Collection and culture of oocytes. Oocytes were collected from 8,12-week-old
females following standard super-ovulation by serial intraperitoneal injection of 5 IU
pregnant mare serum gonadotropin (PMSG) and 5 IU human chorionic
gonadotropin (hCG). Oviductal metaphase II (mII) oocytes were collected in M2
medium (SpecialtyMedia, USA),15 h post-hCG injection essentially as described34.
After repeated washing in M2, denuded oocytes were incubated in kalium simplex
optimizedmedium (KSOM; Specialty Media, USA)35 under mineral oil in humidified
5% CO2 (v/v air) at 37uC, until required.
Sperm preparation and microinjection. Sperm preparation was essentially as
previously described21,22. Briefly, cauda epididymidal sperm from 8,12-week-old
males were triturated for 45 sec in nuclear isolation medium (NIM; 125 mM KCl,
2.6 mM NaCl, 7.8 mM Na2HPO4, 1.4 mM KH2PO4, 3.0 mM EDTA; pH 7.0)
containing 1.0% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) at room temperature (25uC). Sperm were washed twice
in NIM and pelleted (1,890 g) at ambient temperature; head-tail detachment was
enhanced by trituration during pellet resuspension. Sperm were resuspended in ice-
cold NIM (,0.5 ml per epididymis) and stored at 4uC for up to 3 h until injection.
Typically, ,50 ml of each suspension was mixed with 20 ml of polyvinylpyrrolidone
(PVP, average Mr < 360,000; Sigma, UK) solution (15% [w/v]) and sperm injected
(ICSI) using a piezo-actuated pipette (Prime Tech, Japan) into oocytes in a droplet of
M2 within ,60 min, essentially as described34. Assuming an inner pipette tip
diameter of 6 mm, we estimate that 2,2.5 pl were introduced per injection. After a
brief (5,15 min) recovery period, injected oocytes were transferred to KSOM under
mineral oil equilibrated in humidified 5% CO2 (v/v air) at 37uC.
Immunocytochemistry and imaging. Immunocytochemistry, differential
interference contrast microscopy (DIC) and fluorescence imaging were essentially as
described previously21,22. In brief, mII oocyte and 1-cell embryo samples for the
images in Figure 2E were incubated overnight at 4uC with mouse anti-a-tubulin
(152000 [v/v]; Sigma) or -H1 (151000; Santa Cruz, USA) antibodies, followed by a
1 h incubation at 37uC with secondary antibody (15250; Life Technologies Ltd., UK)
conjugated to Alexa 488. DNA was stained by incubating samples at 37uC for 20 min
in propidium iodide (15200; Sigma, USA). Fluorescence was visualized on an Eclipse
E600 (Nikon, Japan) microscope equipped with a Radiance 2100 laser scanning
confocal system (BioRad, USA). Images were processed with ImageJ (http://imagej.
nih.gov/ij/) analysis software. Embryos were imaged on an Olympus IX71 equipped
with an Andro Zyla sCMOS camera and OptoLED illumination system (Cairn
Research Ltd., UK) and processed using Metamorph software (Molecular Devices,
LLC, USA). Excitation at 484 nm with an ET-EYFP filter system was used to detect
eGFP epifluorescence. Imaging of blastocysts for Figure 1 and Supplementary Figure
S1 was following culture in drops of KSOM (Specialty Media, USA) under mineral oil
in 6 cm dishes in a humidified 5% CO2 (v/v air) incubator at 37uC21,22.
Embryo transfer. E1.5 (2-cell) embryos (the day following activation) were
transferred to the oviductal ampullae of pseudo-pregnant CD-1 females at day 0.5 (ie
plugged females that had been mated with vasectomized males the previous night).
Pups were delivered by natural birth and where appropriate, fetuses, pups and
placentae collected by Caesarian section at the desired time point. Newborn pups
were fostered by CD-1 females as appropriate.
Vector construction. For target gRNA synthesis, we employed the pT7-gRNA
backbone vector system36. Target gRNA sequences were selected using the CRISPR
gRNA design tool (DNA 2.0) and informed the design of complementary
oligonucleotides of the general sequences: TAGGN20 (forward) and AAACN20
(reverse)(Eurofins MWG Operon). Forward and reverse oligonucleotides (10 mM
each)were annealed by incubating in 20 ml 13NEBbuffer solution at 95uC for 5 min,
ramping down to 50uC at 0.1uC/sec followed by 50uC for 10 min then ramping to 4uC
at 1uC/sec. 1 ml of annealed oligonucleotides were mixed with 400 ng of pT7-gRNA
vector, 0.5 ml BsmBI, 0.3 ml BglII, 0.3 ml SalGI, 0.5 ml T4 DNA ligase, 1 ml 103 NEB
buffer 3, 1 ml T4 ligase buffer and 4 ml nuclease-free water. One-step digestion and
ligation were performed in a PCR machine using the parameters: 3 cycles of 37uC for
20 min, 16uC for 15 min, followed by incubation at 37uC for 10 min and 55uC for
15 min. Products (2 ml) were used to transform DH5a. Positives (.90%) were
verified by diagnostic BglII digestion and sequencing and purified pT7-gRNA
constructs were linealized by BamH1 digestion and used to program in vitro gRNA
synthesis using a MEGAscript T7 Transcription Kit (Life Technologies).
Synthesis of cRNA and gRNA. 59-capped and polyadenylated Cas9 cRNA was
synthesized in a T7mScriptTM Standard mRNA Production System (Cellscript, USA)
as previously described21,22 from the T7 P3s-Cas9HC vector. Guide RNA (gRNA) was
synthesized using a MEGAshortscript T7 Transcription Kit (Invitrogen, USA)
according to the instructions of the manufacturer. RNAs were dissolved in nuclease-
free water, quantified on a nanophotometer (Implen, Germany) and stored in
aliquots at280uC until required. Immediately prior to injection, RNA solutions were
diluted as appropriate with nuclease-free water. In the sequential injection method,
oocytes were first injected with Cas9 cRNA solution and following culture for 3,4 h
the same oocyte was injected with a single sperm in the appropriate gRNA dilution.
For 1-step injection, gRNA and Cas9 cRNA were mixed with a sperm suspension to
give the appropriate final injection concentrations and a single sperm injected into the
oocyte. Following injection, embryos were cultured in vitro either to the blastocyst
stage to allow evaluation of genome editing in preimplantation embryos, or
transferred at the 2-cell stage to pseudopregnant recipients so that mutations could be
characterised in offspring.
Genomic DNA analysis. For standard genotyping, mouse ear-punch tissue samples
were digested at 55uC for 3 h in 25–100 ml of a lysis buffer containing 10% (w/v)
sodium dodecyl sulphate and with 2 mg/ml proteinase K (Sigma). 1 ml of a 1510
dilution of each sample was used for genotyping by PCR in a 20 ml reaction volume.
For genomic qPCR, crude lysates were diluted 50-fold and 5 ml mixed with 20 ml
SYBRH Green PCR Master Mix (Life Technologies). qPCR was performed on an
ABI7500 Real Time PCR machine (Applied Biosystems) with the following para-
meters: 95uC, 10 sec (once); 95uC, 5 sec; 62uC, 31 sec (40 cycles); 72uC, 35 sec (once).
DNA from the Nanog-eGFP line served as a single eGFP copy reference. Relative
expression of EGFP was calculated using the DCt between eGFP and H3f3a. Fold
change was calculated as E52-DDCt. Sequences of PCR primers used here are given in
Supplementary Table S1.
Whole genome amplification of single oocytes 3 h post-ICSI was performed with a
GenomePlexH Single Cell Whole Genome Amplification kit (Sigma) in accordance
with the supplied instructions. In brief, mII oocytes from superovulated B6D2F1
females were injected with sperm from either 129-GFP homozygous or hemizygous
8,12-week-old males. Injected cells were singly transferred to a 0.2 ml PCR tube in a
minimal volume 3 h after ICSI and flash-frozen until processing shortly after. Frozen
samples were adjusted to 9 ml with nuclease-free water and single-cell lysis and DNA
fragmentation were performed by heating to 50uC for 1 h followed by 99uC for 4 min
in the presence of 1 ml Proteinase K (0.5 mg/ml) in the Single Cell Lysis &
Fragmentation Buffer provided. Library preparation was performed on fragmented
DNA samples using the solution provided and incubated in a thermal cycler with the
Table 1 | Development of embryos and phenotypes of offspring in experiments to edit Tyr alleles
method
in vitro in vivo
[gRNA] [Cas9 cRNA] survived pn 2-cell blast born/tf preg/tf white mosaic % phen
1-step Tyr30 30 ng/ml 148/160 136 132 19/26 60/106 7/7 0 9 15.8
1-step Tyr30 1 Fox30 30 ng/ml 129/148 128 127 17/25 11/60 1/3 0 2 20.0
1-step Tyr 200 100 ng/ml 59/67 57 56 7/8 28/48 3/3 2 4 24.0
1-step Tyr200 1 Fox200 100 ng/ml 54/67 51 48 nd 31/48 3/3 0 5 17.9
seq Tyr30 1 Fox30 30 ng/ml 84/93 78 78 8/18 30/60 3/3 2 2 14.8
Experiments were initiated on$2 experimental days for each treatment. seq, sequential method (Fig. 1A); Tyr30, Tyr gRNA at 30 ng/ml; Fox30, Foxn1 gRNA at 30 ng/ml; pn, pronclear embryos 6,8 h
after sperm injection; blast, blastocyst; nd, not determined; tf, embryo transfer at the 2-cell stage; preg, number of recipients (recipients falling pregnant). Mosaic phenotypes group coat colour and eye
changes. Some pups were rejected by foster mothers prior to weaning. Percentages with phenotype changes (% phen) exclude pups that died perinatally.
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following parameters (one cycle): 16uC, 20 min; 24uC, 20 min; 37uC, 20 min; 75uC,
5 min; hold at 4uC. Genome amplification was performed with the addition of 7.5 ml
AmplificationMasterMix and 5.0 mlWGADNApolymerase in a thermal cycler with
the following parameters immediately after a single denaturing step (95uC, 3 min):
94uC, 30 sec; 65uC, 5 min (25 cycles); hold at 4uC. Using WGA samples as input
DNA, eGFP sequences were amplified by PCR (Supplementary Table S1) and
amplimers purified from 1.4% (w/v) agarose gels using theWizardH SV Gel and PCR
Clean-Up System (Promega) and supplied for sequencing with mixed read sequences
(Source BioScience).
Statistical analysis. Statistical differences between pairs of data sets were analyzed by
a chi-squared test.
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